Nonresolving inflammation underpins several prevalent diseases, including atherosclerosis and Alzheimer disease. The resolution of inflammation is an active process that tempers pro-inflammatory pathways and promotes tissue repair. Understanding the mechanisms that boost endogenous resolution is important for the design of new treatment strategies for nonresolving diseases.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Randomized, double-blind, placebo-controlled study to evaluate the effect of treatment with an SPMs-enriched oil on chronic pain and inflammation, functionality, and quality of life in patients with symptomatic knee osteoarthritis: GAUDI study
Journal of Translational Medicine Open Access 29 June 2023
-
Classification of patients with Alzheimer’s disease using the arterial pulse spectrum and a multilayer-perceptron analysis
Scientific Reports Open Access 26 April 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yin, C. et al. ApoE attenuates unresolvable inflammation by complex formation with activated C1q. Nat. Med. 25, 496–506 (2019).
Serhan, C. N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92–101 (2014).
Chiang, N. et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484, 524–528 (2012).
Fredman, G. et al. Self-limited versus delayed resolution of acute inflammation: temporal regulation of pro-resolving mediators and microRNA. Sci. Rep. 2, 639 (2012).
Fredman, G. et al. An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat. Commun. 7, 12859 (2016).
Tabas, I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10, 36–46 (2010).
Viola, J. R. et al. Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice. Circ. Res. 119, 1030–1038 (2016).
Wang, X. et al. Resolution of inflammation is altered in Alzheimer’s disease. Alzheimers Dement. 11, 40–50 (2015).
Mahley, R. W. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J. Mol. Med. 94, 739–746 (2016).
Knouff, C. et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J. Clin. Invest. 103, 1579–1586 (1999).
Acknowledgements
The author is supported by the NIH (grants HL119587 and HL141127).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Fredman, G. Resolving atherosclerosis and Alzheimer disease. Nat Rev Cardiol 16, 259–260 (2019). https://doi.org/10.1038/s41569-019-0182-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-019-0182-5
This article is cited by
-
Randomized, double-blind, placebo-controlled study to evaluate the effect of treatment with an SPMs-enriched oil on chronic pain and inflammation, functionality, and quality of life in patients with symptomatic knee osteoarthritis: GAUDI study
Journal of Translational Medicine (2023)
-
Classification of patients with Alzheimer’s disease using the arterial pulse spectrum and a multilayer-perceptron analysis
Scientific Reports (2021)
-
Role of Heat Shock Protein 27 in Modulating Atherosclerotic Inflammation
Journal of Cardiovascular Translational Research (2021)
-
Herpud1 deficiency could reduce amyloid-β40 expression and thereby suppress homocysteine-induced atherosclerosis by blocking the JNK/AP1 pathway
Journal of Physiology and Biochemistry (2020)
